JNJ vs. LLY: Johnson & Johnson vs. Eli Lilly Stock Comparison

August 16, 2026

How do Johnson & Johnson (JNJ) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Johnson & Johnson (JNJ) and Eli Lilly (LLY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Profile Item	JNJ	LLY
Name	Johnson & Johnson	Eli Lilly and Company
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	627.42 billion USD	1,052.40 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	January 2, 1962	June 1, 1972
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

JNJ

LLY

GSPC

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Johnson & Johnson (JNJ) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Johnson & Johnson (JNJ) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
Total Return (1Y)	52.73%	73.90%
Total Return (3Y, Annualized)	17.89%	30.83%
Total Return (5Y, Annualized)	11.20%	36.13%

Risk Profile

Drawdown History

JNJ

LLY

GSPC

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Johnson & Johnson (JNJ) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
Volatility (1Y, Annualized)	18.30%	35.66%
Beta (5Y)	0.24	0.50
Max Drawdown (5Y)	-18.41%	-34.48%
Avg. Volume (3M)	8.14M	2.97M

Risk-Adjusted Performance

Risk-Return Positioning

JNJ and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
Sharpe Ratio (1Y)	2.67	1.96
Sortino Ratio (1Y)	4.34	3.41

Profitability

ROE (TTM)

Both companies show strong equity returns, but Eli Lilly (LLY) at 102.29% is the standout with ROE above its industry range; Johnson & Johnson (JNJ) at 25.74% also sits in the top quartile.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max: 100.28%
JNJ: 25.74%
Q3: 3.43%
Median: -33.05%
Q1: -62.24%
Min: -157.61%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

102.29%

LLY: 102.29%
Max: 100.28%
Q3: 3.43%
Median: -33.05%
Q1: -62.24%
Min: -157.61%

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Johnson & Johnson (JNJ) at 21.48% and Eli Lilly (LLY) at 33.53% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.48%

JNJ: 21.48%
Max: 13.44%
Q3: 3.18%
Median: 0.00%
Q1: -4.14%
Min: -14.36%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.53%

LLY: 33.53%
Max: 13.44%
Q3: 3.18%
Median: 0.00%
Q1: -4.14%
Min: -14.36%

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Johnson & Johnson (JNJ) at 29.19% and Eli Lilly (LLY) at 54.22% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.19%

Max: 76.04%
JNJ: 29.19%
Q3: 10.89%
Median: 0.00%
Q1: -122.64%
Min: -308.66%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

54.22%

Max: 76.04%
LLY: 54.22%
Q3: 10.89%
Median: 0.00%
Q1: -122.64%
Min: -308.66%

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
ROE (TTM)	25.74%	102.29%
ROA (TTM)	8.60%	20.36%
Net Margin (TTM)	21.48%	33.53%
Operating Margin (TTM)	29.19%	54.22%
Gross Margin (TTM)	68.14%	83.40%

Growth

Revenue Growth

Both Johnson & Johnson (JNJ) at 6.05% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Johnson & Johnson (JNJ) at 90.50% and Eli Lilly (LLY) at 95.99% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
Revenue Growth (YoY)	6.05%	44.70%
Revenue Growth (3Y CAGR)	5.60%	31.69%
EPS Growth (YoY)	90.50%	95.99%
EPS Growth (3Y CAGR)	17.90%	51.71%

Financial Strength

Current Ratio (MRQ)

Both Johnson & Johnson (JNJ) at 1.09 and Eli Lilly (LLY) at 1.36 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Max: 26.78
Q3: 12.43
Median: 5.72
Q1: 2.77
JNJ: 1.09
Min: 0.10

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.36

Max: 26.78
Q3: 12.43
Median: 5.72
Q1: 2.77
LLY: 1.36
Min: 0.10

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Johnson & Johnson (JNJ) at 0.58 is near its industry mid-range for debt-to-equity ratio, while Eli Lilly (LLY) at 1.62 sits above its benchmark range, pointing to a heavier debt load relative to equity.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.58

Max: 1.48
Q3: 0.64
JNJ: 0.58
Median: 0.14
Q1: 0.02
Min: 0.00

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.62

LLY: 1.62
Max: 1.48
Q3: 0.64
Median: 0.14
Q1: 0.02
Min: 0.00

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
Current Ratio (MRQ)	1.09	1.36
Debt / Equity (MRQ)	0.58	1.62
Net Debt / EBITDA	0.81	1.10

Dividends

Dividend Yield (TTM)

Both Johnson & Johnson (JNJ) at 2.00% and Eli Lilly (LLY) at 0.54% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.00%

JNJ: 2.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.54%

LLY: 0.54%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Johnson & Johnson (JNJ) at 60.79% and Eli Lilly (LLY) at 21.69% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.79%

JNJ: 60.79%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.69%

LLY: 21.69%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
Dividend Yield (TTM)	2.00%	0.54%
Dividend Payout Ratio (TTM)	60.79%	21.69%

Valuation

P/E Ratio (TTM)

Both Johnson & Johnson (JNJ) at 30.20 and Eli Lilly (LLY) at 39.68 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.20

Max: 77.53
Q3: 41.75
JNJ: 30.20
Median: 27.59
Q1: 15.21
Min: 0.13

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.68

Max: 77.53
Q3: 41.75
LLY: 39.68
Median: 27.59
Q1: 15.21
Min: 0.13

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Johnson & Johnson (JNJ) at 6.41 and Eli Lilly (LLY) at 13.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.41

Max: 73.14
Q3: 31.51
Median: 7.39
JNJ: 6.41
Q1: 3.47
Min: 0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.20

Max: 73.14
Q3: 31.51
LLY: 13.20
Median: 7.39
Q1: 3.47
Min: 0.01

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Johnson & Johnson (JNJ) at 7.38 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 33.80 prices above its benchmark range — LLY looks rich relative to book.

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.38

Max: 15.18
Q3: 7.45
JNJ: 7.38
Median: 3.92
Q1: 1.79
Min: -5.47

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.80

LLY: 33.80
Max: 15.18
Q3: 7.45
Median: 3.92
Q1: 1.79
Min: -5.47

Johnson & Johnson (JNJ) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Johnson & Johnson (JNJ) and Eli Lilly (LLY)
Metric	JNJ	LLY
P/E Ratio (TTM)	30.20	39.68
P/S Ratio (TTM)	6.41	13.20
P/B Ratio (MRQ)	7.38	33.80
Free Cash Flow Yield (TTM)	2.69%	1.05%